286-300 of 366

Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer
MinuteCE®Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer

Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer
MinuteCE®Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer

Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors
MinuteCE®Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors

Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
MinuteCE®Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances

Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances
MinuteCE®Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances
- advertisement

Case Application: Patients With EGFRm Resistance Post TKI and Platinum Chemotherapy
MinuteCE®Case Application: Patients With EGFRm Resistance Post TKI and Platinum Chemotherapy

Case Application: Adverse Event Management of Patients With EGFRm Resistance Treated With Novel HER3-Directed ADCs
MinuteCE®Case Application: Adverse Event Management of Patients With EGFRm Resistance Treated With Novel HER3-Directed ADCs

Expert Peer Discussion: Integrating Novel HER3-Directed ADCs Upon Disease Progression Following EGFR TKI and Platinum Chemotherapy
MinuteCE®Expert Peer Discussion: Integrating Novel HER3-Directed ADCs Upon Disease Progression Following EGFR TKI and Platinum Chemotherapy

Biologic Rationale for Targeting HER3 and Role in EGFR Resistance
MinuteCE®Biologic Rationale for Targeting HER3 and Role in EGFR Resistance

Overcoming EGFR Resistance With HER3-Directed ADCs
MinuteCE®Overcoming EGFR Resistance With HER3-Directed ADCs

Interprofessional Monitoring and Management of AEs With HER3-Directed ADCs
MinuteCE®Interprofessional Monitoring and Management of AEs With HER3-Directed ADCs
- advertisement

Differentiating Biomarker-Driven First-Line Treatment Strategies in Metastatic Gastric/GEJ Cancers
CME/CE Broadcast ReplayDifferentiating Biomarker-Driven First-Line Treatment Strategies in Metastatic Gastric/GEJ Cancers

Application of guidelines-recommended broad molecular profiling to patients with NSCLC
MinuteCE®Application of guidelines-recommended broad molecular profiling to patients with NSCLC






























